Jet Lag Superdrug, 25% Dementia Drop, Coffee Brain Aging, Kratom Shakeup : 1415 Podcast Por  arte de portada

Jet Lag Superdrug, 25% Dementia Drop, Coffee Brain Aging, Kratom Shakeup : 1415

Jet Lag Superdrug, 25% Dementia Drop, Coffee Brain Aging, Kratom Shakeup : 1415

Escúchala gratis

Ver detalles del espectáculo
This episode covers: • Mic-628 Could Reset Your Body Clock and Cut Jet Lag in Half A new circadian drug candidate, Mic-628, has demonstrated the ability to shift the body’s internal clock and significantly reduce jet-lag recovery time in early human studies. In controlled simulations, participants experienced faster realignment of their sleep-wake cycles and improved daytime performance compared to standard approaches like melatonin and light timing alone. Dave explains how this compound targets a core clock pathway, why eastbound travel is biologically harder than westbound, and how pharmacologic chronotherapy could become a serious performance tool for frequent travelers and shift workers. He also connects circadian alignment to obesity, insulin resistance, cardiovascular risk, and cognitive decline, outlining what this breakthrough could mean if safety data continues to hold. • Source: https://www.sciencedaily.com/news/top/ • Late-Life Depression May Signal Parkinson’s or Dementia New research from Shanghai Jiao Tong University found that new-onset depression in older adults is strongly associated with increased risk of Parkinson’s disease and dementia. Dave reframes this finding as a brain health signal rather than a purely psychiatric issue, explaining how inflammation, microglial activation, vascular health, and neurodegeneration intersect with mood changes. He breaks down why sudden depression in someone with no prior history may warrant deeper cognitive testing, sleep evaluation, and metabolic screening instead of simply prescribing an antidepressant and moving on. This story highlights the importance of treating mood shifts as early biological data in a longevity framework. • Source: https://www.sciencedaily.com/releases/2026/02/260210040623.htm • Speed-Training Brain Games Reduced Dementia Risk by 25 Percent The long-running NIH-funded ACTIVE trial found that a specific speed-of-processing training program reduced dementia incidence by roughly 25 percent over two decades. Unlike memory or reasoning exercises, this visual processing speed protocol produced measurable long-term protection. Dave explains why reaction time and processing speed may be core capacities tied to cognitive resilience, and how structured brain-training programs descended from this research can be treated like strength training for the mind. Instead of vague advice to “stay mentally active,” this data supports building deliberate, trackable cognitive training into a midlife longevity plan. • Sources: – NPR summary: https://www.npr.org/2026/02/09/nx-s1-5702423/modest-mental-exercise-can-reduce-risk-of-dementia-for-decades-study-finds – Psychology Today analysis: https://www.psychologytoday.com/us/blog/build-your-brain/202602/new-study-means-the-age-of-dementia-prevention-begins-now • Moderate Coffee Intake Linked to Slower Brain Aging A large analysis of roughly 130,000 participants found that moderate coffee consumption, about one to three cups daily, was associated with markers of slower brain aging and lower dementia risk. Dave explains why moderate, morning-weighted caffeine intake may align acute performance benefits with potential long-term brain protection. He breaks down the dose curve, why more is not necessarily better, and how to use coffee strategically without compromising sleep or circadian rhythm. Rather than framing caffeine as either a miracle or a villain, this study supports intelligent, personalized dosing as part of a broader brain-health stack. • Source: https://www.nature.com/articles/d41586-026-00409-y • Kratom Crackdowns and the Future of Supplement Freedom Regulators are tightening restrictions on high-potency kratom derivatives such as 7-hydroxymitragynine, with new bans and stricter warning requirements emerging at the state level. The FDA continues to treat kratom and its concentrated derivatives as unapproved drugs with opioid-like effects, while local jurisdictions are targeting specific formulations linked to adverse events. Dave breaks down how this represents a broader shift in how edge-case compounds are regulated, why supply volatility and underground markets can increase risk, and what this means for biohackers who experiment with gray-area tools. He also explains how evolving enforcement strategies could shape future access to peptides, nootropics, and other advanced compounds. • Sources: – Kansas City coverage: https://www.kshb.com/news/local-news/strong-high-weak-laws-7-oh-ban-kratom-regulation-moves-forward-in-kansas-city-missouri – Florida policy coverage: https://www.wgcu.org/health/2026-02-04/kratom-advocates-tout-its-properties-but-legislators-want-strict-warnings-about-the-herbal-supplement – Legal landscape analysis: https://www.lumalexlaw.com/2025/10/09/kratoms-legal-future-how-states-and-the-federal-government-are-responding/ – FDA background: https://www.fda.gov/news-events/...
Todavía no hay opiniones